vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $16.9M, roughly 1.2× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 6.9%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-2.0M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 2.9%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
FVCB vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $20.4M |
| Net Profit | — | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 43.7% | -18.0% |
| Net Margin | — | -20.4% |
| Revenue YoY | 4377.5% | 6.9% |
| Net Profit YoY | — | 64.9% |
| EPS (diluted) | $0.31 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $20.4M | ||
| Q3 25 | $416.0K | $19.9M | ||
| Q2 25 | $15.8M | $19.6M | ||
| Q1 25 | $382.0K | $17.5M | ||
| Q4 24 | $378.0K | $19.1M | ||
| Q3 24 | $412.0K | $20.2M | ||
| Q2 24 | $415.0K | $21.4M | ||
| Q1 24 | $359.0K | $19.3M |
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $5.6M | $-8.2M | ||
| Q2 25 | $5.7M | $-11.9M | ||
| Q1 25 | $5.2M | $-14.2M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | $4.7M | $-11.1M | ||
| Q2 24 | $4.2M | $-12.3M | ||
| Q1 24 | $1.3M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 43.7% | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | 45.9% | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% | ||
| Q1 24 | — | -76.4% |
| Q4 25 | — | -20.4% | ||
| Q3 25 | 1341.1% | -41.0% | ||
| Q2 25 | 36.0% | -61.0% | ||
| Q1 25 | 1352.1% | -80.8% | ||
| Q4 24 | — | -62.1% | ||
| Q3 24 | 1133.3% | -54.9% | ||
| Q2 24 | 1001.2% | -57.7% | ||
| Q1 24 | 373.3% | -84.4% |
| Q4 25 | $0.31 | $-0.07 | ||
| Q3 25 | $0.31 | $-0.16 | ||
| Q2 25 | $0.31 | $-0.23 | ||
| Q1 25 | $0.28 | $-0.28 | ||
| Q4 24 | $0.27 | $-0.23 | ||
| Q3 24 | $0.25 | $-0.22 | ||
| Q2 24 | $0.23 | $-0.25 | ||
| Q1 24 | $0.07 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $253.6M | $63.9M |
| Total Assets | $2.3B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $253.6M | $63.9M | ||
| Q3 25 | $249.8M | $64.3M | ||
| Q2 25 | $243.2M | $70.0M | ||
| Q1 25 | $242.3M | $77.6M | ||
| Q4 24 | $235.4M | $87.5M | ||
| Q3 24 | $230.8M | $95.0M | ||
| Q2 24 | $226.5M | $101.6M | ||
| Q1 24 | $220.7M | $109.2M |
| Q4 25 | $2.3B | $115.3M | ||
| Q3 25 | $2.3B | $116.3M | ||
| Q2 25 | $2.2B | $122.0M | ||
| Q1 25 | $2.2B | $129.7M | ||
| Q4 24 | $2.2B | $142.8M | ||
| Q3 24 | $2.3B | $143.6M | ||
| Q2 24 | $2.3B | $149.7M | ||
| Q1 24 | $2.2B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-1.8M |
| Free Cash FlowOCF − Capex | $23.8M | $-2.0M |
| FCF MarginFCF / Revenue | 140.7% | -9.7% |
| Capex IntensityCapex / Revenue | 0.3% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $-1.8M | ||
| Q3 25 | $7.6M | $-8.7M | ||
| Q2 25 | $3.3M | $-7.5M | ||
| Q1 25 | $5.4M | $-11.6M | ||
| Q4 24 | $18.2M | $-3.5M | ||
| Q3 24 | $4.7M | $362.0K | ||
| Q2 24 | $1.6M | $-9.5M | ||
| Q1 24 | $7.2M | $-9.8M |
| Q4 25 | $23.8M | $-2.0M | ||
| Q3 25 | $7.6M | $-8.9M | ||
| Q2 25 | $3.3M | $-7.8M | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $18.1M | $-3.6M | ||
| Q3 24 | $4.6M | $311.0K | ||
| Q2 24 | $1.5M | $-9.5M | ||
| Q1 24 | $7.1M | $-9.9M |
| Q4 25 | 140.7% | -9.7% | ||
| Q3 25 | 1818.0% | -44.7% | ||
| Q2 25 | 20.8% | -39.6% | ||
| Q1 25 | 1413.6% | — | ||
| Q4 24 | 4786.0% | -18.9% | ||
| Q3 24 | 1121.8% | 1.5% | ||
| Q2 24 | 361.2% | -44.7% | ||
| Q1 24 | 1988.3% | -51.4% |
| Q4 25 | 0.3% | 0.8% | ||
| Q3 25 | 0.2% | 0.9% | ||
| Q2 25 | 0.1% | 1.1% | ||
| Q1 25 | 4.2% | 0.0% | ||
| Q4 24 | 37.3% | 0.7% | ||
| Q3 24 | 14.1% | 0.3% | ||
| Q2 24 | 12.8% | 0.4% | ||
| Q1 24 | 3.9% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
